Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209038 | 1.00 | NOS1 (0.46) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL29271546 | 0.82 | NOS1 (0.43) | NOS1CTSAAPLNR | |
| SCHEMBL2600726 | 0.80 | NOS1 (0.44) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL30209104 | 0.77 | — | — | |
| SCHEMBL1160475 | 0.77 | AAK1 (0.41) | NOS1CTSAAPLNRALDH1A1 | |
| SCHEMBL6010207 | 0.76 | NOS1 (0.41) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL20738686 | 0.76 | NOS1 (0.41) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL12179230 | 0.76 | NOS1 (0.41) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL11458946 | 0.76 | NOS1 (0.41) | NOS1CTSAAPLNRALDH1A1GAA | |
| SCHEMBL12848866 | 0.73 | NOS1 (0.38) | NOS1CTSAAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
| US-7598258-B2 | N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | CSF3R, CSF1R, MSR1 | NOS1 941/4885CTSA 733/4885APLNR 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.